Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Aug 3;61(8):3279-3288.
doi: 10.1093/rheumatology/keab887.

Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis

Ann-Sophie De Craemer  1   2 , Thomas Renson  1   2 , Liselotte Deroo  1   2 , Liesbet Van Praet  3 , Heleen Cypers  4 , Gaëlle Varkas  1 , Rik Joos  1   5 , Mieke Devinck  6 , Lieve Gyselbrecht  7 , Isabelle Peene  1   8 , Kristof Thevissen  4   9 , Félicie Costantino  10   11 , Maria-Antonietta D'Agostino  10   11   12 , Jan Lenaerts  13   14 , Philippe Carron  1   2   15 , Filip Van den Bosch  1   2 , Dirk Elewaut  1   2
Affiliations
Observational Study

Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis

Ann-Sophie De Craemer et al. Rheumatology (Oxford). .

Erratum in

Abstract

Objectives: To delineate the impact of peripheral musculoskeletal manifestations on stratification of disease phenotype and outcome in new-onset spondyloarthritis (SpA), using a prospective observational nationwide inception cohort, the BelGian Inflammatory Arthritis and spoNdylitis cohorT (Be-Giant).

Methods: Newly diagnosed adult SpA patients, fulfilling the Assessment of SpondyloArthritis International Society (ASAS) criteria for axial or peripheral SpA, were included in Be-Giant and prospectively followed every six months. Peripheral involvement (defined as arthritis, enthesitis and/or dactylitis) was determined in relation to clinically similar patient subsets at baseline and disease activity patterns during two-year follow-up, identified through K-means cluster analysis and latent class growth analysis.

Results: From November 2010 to March 2020, 367 patients were enrolled in Be-Giant, of whom 162 (44%) had peripheral manifestations. Two patient clusters [A, axial predominant (n = 248) and B, peripheral predominant (n = 119)] were identified at diagnosis. Longitudinal analysis (n = 115) revealed two trajectories of disease activity in each cluster: one with persistently high disease activity over time ('High'), the other rapidly evolving to low disease activity ('Low'). In cluster A patients, peripheral manifestations predisposed to the 'High' trajectory [odds ratio (OR) = 2.0, 95% CI: 1.3, 3.1, P = 0.001], despite more rapid initiation of biologics compared with patients without peripheral manifestations (hazard ratio (HR) = 2.1, 95% CI: 1.0, 4.4, P = 0.04 - Cox proportional-hazards model).

Conclusion: Peripheral musculoskeletal manifestations are major determinants of phenotypical diversity in new-onset SpA. Intriguingly, stratification of axial SpA according to concomitant peripheral involvement identified an endotype with an unfavorable outcome despite more prompt therapeutic intensification with biologics. These observations justify an endotype-tailored approach beyond current ASAS/EULAR management recommendations.

Keywords: clusters; peripheral manifestations; spondyloarthritis; trajectories.

PubMed Disclaimer

Publication types

Substances

LinkOut - more resources